Michael J. Mclane

Hematology Oncology | Hematology | Oncology

145 Michigan St Ne
Suite 3100
Grand Rapids, MI 49503

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3 publications

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.

Journal: Nature

Published: July 21, 2017

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: September 30, 2016

Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.

Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.

Journal: Experimental hematology

Published: September 26, 2016

Showing 1-3 of 3

Last Updated: 09/26/2026